44 filings
Page 2 of 3
8-K
bfhawyki
9 May 22
ORIC Pharmaceuticals Reports First Quarter 2022
4:10pm
8-K
odbl87
21 Mar 22
Regulation FD Disclosure
5:12pm
8-K
nf5tvhqy
21 Mar 22
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2021
4:07pm
8-K
dpxopo0g3
4 Mar 22
Departure of Directors or Certain Officers
4:02pm
8-K
fit78 hhs
10 Jan 22
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones
8:07am
8-K
vvixkltyvrdte
10 Nov 21
ORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of Directors
4:21pm
8-K
g0z7r8itzlcd46zc 2xn
8 Nov 21
ORIC Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update
4:16pm
8-K
s0ez6dqrke jxj
7 Oct 21
ORIC Pharmaceuticals Presents Initial Clinical Data from
4:06pm
8-K
3nwuovfl0j61l
18 Aug 21
Other Events
6:07am
8-K
1f19t1vzhnm
16 Aug 21
ORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors
4:41pm
8-K
e3skxt5im5ptt7tkvz6
10 Aug 21
ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update
4:16pm
8-K
65scl97
12 Jul 21
Other Events
5:05pm
8-K
eag804c
8 Jul 21
ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor
6:05am
8-K
yqldf bue
21 Jun 21
ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel
4:06pm
8-K
35ckzoyg 1c
6 May 21
Entry into a Material Definitive Agreement
5:10pm
8-K
m0yy3 sxaej
6 May 21
ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update
4:10pm
8-K
wglpzqxpmq6y y6rkx
23 Mar 21
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020
4:10pm
8-K
8clqy1rtubdb
11 Jan 21
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones
6:36am
8-K
1peeu 6s1z5c7tyj
5 Nov 20
ORIC Pharmaceuticals Reports Third Quarter 2020
4:18pm
8-K
1s2flx9 agck77h
19 Oct 20
Other Events
4:09pm